Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Izalontamab brengitecan (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors Sichuan Baili Pharmaceutical

26 Sep 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2027.
26 Sep 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
03 Aug 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com